
MANUAL

TUBE 2 (Agarose)

Catalog Number: UM402



BACKGROUND

Ubiquitin and Polyubiquitination

Ubiquitin is a small polypeptide that can be conjugated via its C-terminus to amine groups of lysine residues on target proteins. This conjugation is referred to as monoubiquitination. Additional ubiquitin moieties can be conjugated to this initial ubiquitin utilizing any one of the seven lysine residues present in ubiquitin. The formation of these ubiquitin chains is referred to as polyubiquitination. The two most well characterized forms of polyubiquitination occur via linkage at lysine 48 (K48) or lysine 63 (K63). The most prevalent consequence of polyubiquitination is the proteasome-mediated degradation of the target protein. Polyubiquitination is a reversible process, as these chains can be degraded and/or removed by proteases known as deubiquitylases (DUBs). The dynamic nature of this signal represents a major obstacle to the isolation and functional characterization of polyubiquitinated proteins. For this reason, the ubiquitination state of many proteins is unknown or poorly characterized.

TUBEs: A Revolution in Polyubiquitin Isolation and Characterization

Traditional strategies for the characterization of ubiquitinated proteins often require immunoprecipitation of overexpressed ubiquitin with an epitope tag or the use of ubiquitin antibodies (expensive for large scale studies). Alternatively, isolation of polyubiquitinated proteins can be achieved with certain ubiquitin-binding associated domains (UBAs), but these proteins display a low affinity for ubiquitin. Additionally, these strategies require the inclusion of inhibitors of both DUB and proteasome activity to protect the integrity of polyubiquitinated proteins. These conditions could alter cell physiology, which in turn may negatively impact the result or introduce experimental Tandem Ubiquitin Binding Entities (TUBEs) have been developed to overcome these problems (1,2) and they are licensed by LifeSensors, Inc. from Dr. Manuel Rodriquez at CIC bioGUNE. TUBEs are essentially tandem UBAs with dissociation constants for tetra-ubiquitin in the nanomolar range. They have also been shown to protect proteins from both deubiquitination and proteasome-mediated degradation, even in the absence of inhibitors typically required to block such activity. The nanomolar affinity of TUBEs for polyubiquitinated proteins allows for a highly efficient isolation and characterization of these proteins from cell lines and tissues. TUBE1 and TUBE2 have been demonstrated to bind to all 7 linkage types (3). However, being derived from different ubiquitin-binding domains it is expected that TUBE1 and TUBE2 may have different specificity profiles for the various linkage types. The superior nature of TUBEs allows for an efficient detection of polyubiquitinated proteins in their native state, while the versatility of TUBEs meets a wide range of experimental needs.

Agarose-TUBEs are TUBE moieties directly coupled to agarose beads, designed for the identification and characterization of polyubiquitinated proteins by Western blotting and/or downstream proteomic studies. Agarose-TUBEs facilitate convenient "one-step" pull-down of polyubiquitinated proteins.

SUGGESTED USES:

- Convenient one step pull-down of polyubiquitinated proteins from cell and tissue extracts
- 2. Isolation of ubiquitinated proteins for proteomic studies.

BENEFITS:

- 1. TUBEs exhibit up to 1000-fold higher affinity for polyubiquitin compared to the single UBA form.
- **2.** TUBEs offer higher specificity and affinity for polyubiquitin than ubiquitin antibodies.
- **3.** TUBEs help avoid the overexpression of epitope-tagged ubiquitin in pulldown experiments.
- **4.** TUBEs protect polyubiquitinated proteins from degradation during cell lysis and storage.




Figure 1. Schematic of the various TUBEs available from Lifesensors Inc.

COMPONENTS

TUBE 2 (Agarose)

Size: 1 ml of a 50% slurry.

Buffer: PBS, pH 7.2, 20% ethanol.

Storage: -20°C. Avoid storage at lower temperature. Small batches of

equilibrated resin can be stored at 4°C for up to 1 week.

Please note that some physical characteristics and protocols are item specific. Please refer to individual product sheets or application notes available at www.lifesensors.com for further information.

ADDITIONAL ITEMS REQUIRED BUT NOT INCLUDED IN THE KIT

 Cell Lysis buffer: 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol.

The use of alternative buffer systems should not impact TUBE function; however, the inclusion of detergents e.g. (SDS or deoxycholate) may have a negative impact on the overall yield of polyubiquitinated proteins.

The inclusion of a protease inhibitor cocktail is recommended to protect from non-specific protein degradation during lysis and isolation.

- 2. 20 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% Tween-20 (TBST)
- 3. Control agarose (LifeSensors Cat. No. <u>UM400</u>)
- 4. PR-619 (LifeSensors Cat. No. <u>Sl9619</u>). This compound is a reversible inhibitor of a wide range of Ub/Ubl proteases and has been shown to protect polyubiquitinated proteins from degradation. The inclusion of PR-619 in the lysis buffer can increase the yield of polyubiquitinated proteins during the preparation of cell and tissue extracts.
- 5. 1,10-phenanthroline (o-PA), 100X (LifeSensors Cat. No. <u>Sl9649</u>). This metal chelator is a potent inhibitor of metalloproteases, including JAMM DUBs, and helps prevent the degradation of polyubiquitin chains during cell lysis.
- (Optional) N-Ethylmaleimide (NEM), an irreversible inhibitor of all cysteine peptidases.

EQUILIBRATION OF TUBE 2 (AGAROSE)

- 1. Allow the slurry to equilibrate to 4°C by incubating at room temperature for 20-30 min or at 4°C for up to 2 hours. Gently mix Agarose-TUBEs by inverting the vial several times to ensure a homogeneous suspension.
- 2. Determine the amount of resin required for the experiment. The amount of polyubiquitin in samples can vary depending on cell or tissue type, experimental



conditions, and the presence or absence of deubiquitinating enzymes or proteasomal inhibitors. Therefore, the optimal amount of Agarose-TUBEs for pull-down needs to be determined empirically by the end user. A starting point of 10-20 μ l of resin in 500 μ l of lysis buffer containing 1-2 mg of total protein is appropriate for each experiment. Larger volumes (100-150 μ l) of slurry can be equilibrated and stored for up to one week at 4°C

- **3.** Collect the volume of resin necessary for the experiment by low-speed centrifugation (1000-5000xg) for 5 minutes (RT).
- **4.** Remove and discard the supernatant, being careful not to disturb the resin. **Useful tip:** when working with agarose matrices, use gel loading tips to collect supernatants to avoid loss of beads.
- **5.** Suspend the resin in 5-10 volumes of TBS-T and incubate for 5 minutes on a rocker platform at room temperature.
- **6.** Repeat the collection/wash steps (steps 3-5) at least two times before proceeding with the pull-down.
- 7. Remove and discard the final wash supernatant. Make sure to leave a 50% slurry before proceeding to Step 7 of the protocol below.


PULLDOWN OF POLYUBIQUITINATED PROTEINS (SUGGESTED PROTOCOL)

- Pre-chill cell lysis buffer and microcentrifuge tubes to 4°C. Add PR-619 (at a final concentration of 50 μM), o-PA (at a final concentration of 1x), NEM (at a final concentration of 5 mM), and protease inhibitor cocktail (see manufacturer's instructions) to the lysis buffer.
- 2. Treat and wash cells appropriately. As an initial starting point, we recommend the addition of 500 μ L of lysis buffer to a 10 cm² tissue culture dish containing ~5-10x10⁶ cells (80% confluence). The optimal number of cells will depend on the cell line and the abundance of the protein of interest.
- Collect cells by scraping and transfer the lysate to 1.5 mL microcentrifuge tube.
- 4. Clarify lysate by high-speed centrifugation (~14,000xg) for 10 min at 4°C.
- 5. Optional control for non-specific binding: Incubate the clarified cell lysate with uncoupled agarose (Cat. #UM400) for 30 min at 4°C on a rocker platform. Remove agarose by centrifugation and transfer the clarified supernatant to a new 1.5 ml microcentrifuge tube.
- 6. Save an "INPUT" sample for analysis by Western blotting (e.g., 5-20 µl of cell lysate in 25-50 µl 1X SDS reducing sample buffer at the following final concentrations of 62.5 mM Tris-HCL (pH6.8), 1.5% SDS, 8.33% Glycerol, 1.5% β-mercaptoethanol, and 0.005% Bromophenol blue).



- 7. Add the cell lysate to the appropriate amount of equilibrated Agarose-TUBEs determined from step 2 of the previous section. Incubate for 1 hour at 4°C on a rocker platform. Additional incubation time may be required; optimal time should be determined by the end user.
- **8.** Collect beads by low-speed centrifugation (1000-5000xg, 4°C) for 5 minutes. Save the supernatant as the "UNBOUND FRACTION."
- **9.** Wash beads with 1 ml TBS-T. Collect by low-speed centrifugation and aspirate the supernatant, leaving a small volume cushion to avoid disturbing the beads.
- 10. Repeat Step 9 two more times.
- 11. For Western blot analysis, resuspend resin in SDS reducing sample buffer (use of a more concentrated SDS reducing sample buffer may allow for greater flexibility with electrophoresis samples), treat by boiling for 5 minutes, and centrifuge at 13,000xg for 5 minutes. Analyze the eluted samples by SDS-PAGE/Western blotting, alongside the INPUT and the UNBOUND FRACTION. Discard the resin.

REPRESENTATIVE DATA



Enrichment of polyubiquitinated proteins with Agarose-TUBE2 (UM402). HEK293T cells were lysed in TBS containing 5 mM EDTA, 1% NP-40, Protease Inhibitor Cocktail (Calbiochem), 50 μ M PR619 (LifeSensors Cat. # Sl9619), and 5 mM o-phenanthroline (LifeSensors Cat. #Sl9649). Total protein content of pre-cleared (using Control Agarose; LifeSensors cat. # UM400) lysate was determined by Bradford, and 10 μ l of Agarose-TUBE 2 resin (LifeSensors Cat. # UM402) was added to each sample. Samples were incubated by rotation for 3.5 hours at 4°C, washed three times with TBS plus EDTA, and analyzed by SDS-PAGE followed by immunoblotting for ubiquitin using the VU-1 Ubiquitin Monoclonal Antibody (LifeSensors Cat. # ν U101, 1:1000).

REFERENCES

- 1. Stormo, Adrienne ED, Farbod Shavarebi, Molly FitzGibbon, Elizabeth M. Earley, Hannah Ahrendt, Lotus S. Lum, Erik Verschueren et al (2022) "The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity." Journal of Cell Biology 221, no. 4.
- 2. Sarbanes, Stephanie L., Vincent A. Blomen, Eric Lam, Søren Heissel, Joseph M. Luna, Thijn R. Brummelkamp, Erik Falck-Pedersen, H-Heinrich Hoffmann, and Charles M. Rice. (2021) "E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes." Proceedings of the National Academy of Sciences 118, no. 1: e2015794118.
- 3. Hatstat, A. Katherine, Hannah D. Ahrendt, Matthew W. Foster, Leland Mayne, M. Arthur Moseley, S. Walter Englander, and Dewey G. McCafferty. (2021) "Characterization of small-molecule-induced changes in Parkinson's-related trafficking via the Nedd4 ubiquitin signaling cascade." Cell Chemical Biology 28, no. 1: 14-25.
- **4.** Hark, Timothy J., Nalini R. Rao, Charlotte Castillon, Tamara Basta, Samuel Smukowski, Huan Bao, Arun Upadhyay et al. (2021) "Pulse-chase proteomics of the App knockin mouse models of Alzheimer's disease reveals that synaptic dysfunction originates in presynaptic terminals." Cell systems 12, no. 2: 141-158.
- 5. Wolf, Lucie M., Annika M. Lambert, Julie Haenlin, and Michael Boutros. (2021) "EVI/WLS function is regulated by ubiquitylation and is linked to ER-associated degradation by ERLIN2." Journal of cell science 134, no. 16: jcs257790.
- **6.** Jongkamonwiwat, Nopporn, Miguel A. Ramirez, Seby Edassery, Ann CY Wong, Jintao Yu, Tirzah Abbott, Kwang Pak, Allen F. Ryan, and Jeffrey N. Savas. (2020) "Noise exposures causing hearing loss generate proteotoxic stress and activate the proteostasis network." Cell reports 33, no. 8: 108431.
- **7.** Ji, Lei, Bo Lu, Raffaella Zamponi, Olga Charlat, Robert Aversa, Zinger Yang, Frederic Sigoillot et al. (2019) "USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin." Nature communications 10, no. 1: 1-14.
- **8.** Hjerpe, R., Aillet, F., Lopitz-Otsoa F., Lang, V., England P., and Rodriguez, MS. (2009) "Efficient protection andisolation of ubiquitylated proteins using tandem ubiquitin-binding entities." *EMBO Rep.*, 10(11)1250-8.
- **9.** Lopitz-Otsoa F., Rodriguez-Suarez E., Aillet F., Casado-Vela J., Lang V., Matthiesen R., Elortza F., and Rodriguez M.S. (2012) "Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs)" *J. Proteomics*. 75(10):2998-3014.
- 10. Altun, M., Kramer, H.B., Willems, L.I., McDermott, J.L., Leach, C.A., Goldberg, S.J., Suresh Kumar, K.G., Konietzny, R., Fischer R., Kogan, E., MacKeen M.M., Khoronenkova, S. V., Parsons, J.L., Dianov, G. L., Nicholson, B. and Kessler, B.M. (2011) "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes." *Chemistry& Biology*, 18 1401-1212.

LIMITED USE LABEL LICENSE

TUBEs are licensed by LifeSensors, Inc. from Manuel Rodriquez at CIC bioGUNE. For information on obtaining a license for commercial purposes, contact LifeSensors, Inc., Malvern PA 19355, Phone: 610.644.8845 ext 304.

The product and/or its derivatives are being furnished to the purchaser under the following conditions: By purchasing the product, the purchaser agrees to comply with the terms of this Limited Use Label License. The product is provided to purchaser for research use only. The purchaser of this product may not transfer or otherwise sell this product or its derivatives to a third party and no rights are given to the purchaser to use the product or its derivatives for commercial purposes as defined below.

Commercial purposes mean any activity for which a party receives consideration and may include, but is not limited to,

- 1. use of the product or its derivatives in manufacturing,
- 2. use of the product or its derivatives to provide a service, information, or data,
- 3. use of the product or its derivatives for diagnostic purposes,
- transfer or sale of protein or chemical component made with the product or derivatives of the product,
- 5. re-sale of the product or its derivatives, whether or not such product or its derivatives are resold for use in research

Product use must follow compliance with all laws and regulations, including but not limited to current EPA, FDA, USDA, and NIH guidelines. THE MATERIALS WILL NOT BE USED IN HUMANS.

Purchaser acknowledges that the product is experimental in nature and provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. LIFESENSORS, INC. MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS.

In no event shall LifeSensors, Inc. be liable for any use of the product by the purchaser. Purchaser agrees to defend, indemnify, and hold harmless LifeSensors, Inc. Its officers, employees, and agents from any loss, claim, injury, damage, expense, or liability (including attorney's fees), of whatsoever kind or nature, which may arise from or in connection with this Agreement, including but not limited to purchaser use, handling or storage of the product.

all products are for research use only • not intended for human or animal diagnostic or therapeutic uses LifeSensors, Inc., 271 Great Valley Parkway, Malvern PA 19355 • (p) 610.644.8845 (f) 610.644.8616 techsupport@lifesensors.com • www.lifesensors.com • sales@lifesensors.com Copyright © 2010 LifeSensors, Inc. All Rights Reserved

